Early detection of lung cancer: A statement from an expert panel of the swiss university hospitals on lung cancer screening

Respiration

Volumn 87, Issue 3, 2014, Pages 254-264

  Frauenfelder, T ^a   Puhan, M A ^b   Lazor, R ^c   Von Garnier, C ^d   Bremerich, J ^f   Niemann, T ^f   Christe, A ^e   Montet, X ^g   Gautschi, O ^h   Weder, W ^a   Kohler, M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Institute of Social and Preventive Medicine Zürich University   (Canada)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Departments of Pulmonary Medicine   (United States)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h Department of Radiology University Hospital of Basel ^*  (Switzerland)

Author keywords

Early lung cancer detection; Low dose CT; Lung cancer screening

Indexed keywords

CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; LUNG CANCER; LUNG NODULE; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; SWITZERLAND; UNIVERSITY HOSPITAL; ALGORITHM; COMPUTER ASSISTED TOMOGRAPHY; COST; FUNDING; HIGH RISK PATIENT; INFORMATION; INTERPERSONAL COMMUNICATION; MEDICAL SPECIALIST; PUBLICATION; PULMONOLOGIST; QUALITY CONTROL; RADIOLOGIST; REGISTER; SCREENING; SWISS; THORAX RADIOGRAPHY; THORAX SURGERY;

EARLY DETECTION OF CANCER; HOSPITALS, UNIVERSITY; HUMANS; LUNG NEOPLASMS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SWITZERLAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84896107432     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000357049     Document Type: Review

References (77)

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
2. Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, et al: A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med 2009; 180: 445-453.
3. Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK: UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011; 66: 308-313.
4. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al: CT screening for lung cancer brings forward early disease: the randomised Danish Lung Cancer Screening Trial-status after five annual screening rounds with low-dose CT. Thorax 2012; 67: 296-301.
5. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, et al: Riskbased selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007; 120: 868-874. (Pubitemid 46175408)
6. van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, et al: Management of lung nodules detected by volume CT scanning. N Engl J Med 2009; 361: 2221-2229.
7. Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, et al: Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012; 21: 308-315.
8. Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, et al: The American Association for Thoracic Surgery guidelines for lung cancer screening using lowdose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012; 144: 33-38.
9. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Lung Cancer Screening Version 1. 2012. http://www.nccn.org/ professionals/physician-gls/pdf/lung-screening.pdf.
10. Couraud S, Cortot AB, Greillier L, Gounant V, Mennecier B, Girard N, et al: From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the Groupe d'Oncologie de Langue Francaise (GOLF). Ann Oncol 2013; 24: 586-597.
11. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB: Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed-American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e78S-e92S.
12. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW: Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013; 63: 88-105.
13. Boiselle PM, Lynm C, Livingston EH: JAMA patient page: lung cancer screening. JAMA 2013; 309: 1948.
14. Field JK, Baldwin D, Brain K, Devaraj A, Eisen T, Duffy SW, et al: CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax 2011; 66: 736-737.
15. Field JK, Smith RA, Aberle DR, Oudkerk M, Baldwin DR, Yankelevitz D, et al: International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol 2012; 7: 10-19.
16. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al: Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012; 307: 2418-2429.
17. Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, et al: Development of the American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of the American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg 2012; 144: 25-32.
18. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al: Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24:vi89-vi98.
19. Vansteenkiste J, Dooms C, Mascaux C, Nackaerts K: Screening and early detection of lung cancer. Ann Oncol 2012; 23:x320-x327.
20. Russi EW: Lung cancer screening has the potential to safe lives, but shall we do it? Swiss Med Wkly 2011; 141:w13185.
21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
22. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al: SEER Cancer Statistics Review, 1975-2008. Bethesda, National Cancer Institute, 2011. http://seer.cancer.gov/csr/1975-2008/.
23. Bouchardy C, Lutz J, Kühni C: Krebs in der Schweiz, Stand und Entwicklung von 1983 bis 2007. Neuchâtel, NICER und Bundesamt für Statistik, 2011.
24. Tockman MS, Erozan YS, Gupta P, Piantadosi S, Mulshine JL, Ruckdeschel JC: The early detection of second primary lung cancers by sputum immunostaining. LCEWDG Investigators. Lung Cancer Early Detection Group. Chest 1994; 106: 385S-390S. (Pubitemid 24370981)
25. Tockman MS, Mulshine JL: Sputum screening by quantitative microscopy: a new dawn for detection of lung cancer? Mayo Clin Proc 1997; 72: 788-790.
26. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al: Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21: 273S-309S.
27. Payne PW, Sebo TJ, Doudkine A, Garner D, MacAulay C, Lam S, et al: Sputum screening by quantitative microscopy: a reexamination of a portion of the National Cancer Institute Cooperative Early Lung Cancer Study. Mayo Clin Proc 1997; 72: 697-704. (Pubitemid 127758156)
28. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-5958.
29. Miozzo M, Sozzi G, Musso K, Pilotti S, Incarbone M, Pastorino U, et al: Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res 1996; 56: 2285-2288. (Pubitemid 26154074)
30. Melamed MR: Lung cancer screening results in the National Cancer Institute New York study. Cancer 2000; 89: 2356-2362.
31. Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D: Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637. (Pubitemid 24116159)
32. Kubik A, Polak J: Lung cancer detection: results of a randomized prospective study in Czechoslovakia. Cancer 1986; 57: 2427-2437. (Pubitemid 16118986)
33. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR: Lung cancer screening: the Mayo program. J Occup Med 1986; 28: 746-750. (Pubitemid 16055356)
34. Brett GZ: The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968; 23: 414-420.
35. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al: Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011; 306: 1865-1873.
36. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al: Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99-105. (Pubitemid 29313143)
37. Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M: Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248: 254-263.
38. Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, et al: Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169: 2078-2086.
39. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al: Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007; 168: 1-64. (Pubitemid 351292925)
40. van den Bergh KA, Essink-Bot ML, Bunge EM, Scholten ET, Prokop M, van Iersel CA, et al: Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). Cancer 2008; 113: 396-404.
41. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355: 1763-1771. (Pubitemid 44631359)
42. Bach PB: Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax 2008; 63: 298-300. (Pubitemid 351497939)
43. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB: Computed tomography screening and lung cancer outcomes. JAMA 2007; 297: 953-961. (Pubitemid 46376749)
44. Kubik AK, Parkin DM, Zatloukal P: Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. Cancer 2000; 89: 2363-2368.
45. Marcus PM, Bergstralh EJ, Fagerstrom RM, Williams DE, Fontana R, Taylor WF, et al: Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000; 92: 1308-1316. (Pubitemid 30660590)
46. Veronesi G, Maisonneuve P, Bellomi M, Rampinelli C, Durli I, Bertolotti R, et al: Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2012; 157: 776-784.
47. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al: Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013; 369: 245-254.
48. Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al: Selection criteria for lung-cancer screening. N Engl J Med 2013; 368: 728-736.
49. Woloshin S, Schwartz LM, Black WC, Kramer BS: Cancer screening campaigns-getting past uninformative persuasion. N Engl J Med 2012; 367: 1677-1679.
50. American Lung Association: Providing guidance on lung cancer screening to patients and physicians. 2012. http://www.lung.org/lungdisease/lung-cancer/ lung-cancer-screeningguidelines/lung-cancer-screening.pdf (accessed July 5, 2013).
51. American Society of Clinical Oncology: What to know: the ACCP and ASCO guideline on lung cancer screening. 2012. http://www.cancer.net/sites/cancer. net/files/what-to-know-lung-cancer-screening.pdf (accessed May 7, 2013).
52. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J: Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
53. Austin JH, Muller NL, Friedman PJ, Hansell DM, Naidich DP, Remy-Jardin M, et al: Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 1996; 200: 327-331. (Pubitemid 26249879)
54. de Hoop B, van Ginneken B, Gietema H, Prokop M: Pulmonary perifissural nodules on CT scans: rapid growth is not a predictor of malignancy. Radiology 2012; 265: 611-616.
55. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al: Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e93S-e120S.
56. Xu DM, van der Zaag-Loonen HJ, Oudkerk M, Wang Y, Vliegenthart R, Scholten ET, et al: Smooth or attached solid indeterminate nodules detected at baseline CT screening in the NELSON study: cancer risk during 1 year of follow-up. Radiology 2009; 250: 264-272.
57. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, et al: Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237: 395-400. (Pubitemid 41507873)
58. Naidich DP, Bankier AA, Macmahon H, Schaefer-Prokop CM, Pistolesi M, Goo JM, et al: Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner Society. Radiology 2012; 266: 304-317.
59. Godoy MC, Naidich DP: Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology 2009; 253: 606-622.
60. Ahn MI, Gleeson TG, Chan IH, McWilliams AM, Macdonald SL, Lam S, et al: Perifissural nodules seen at CT screening for lung cancer. Radiology 2010; 254: 949-956.
61. Zhao Y, de Bock GH, Vliegenthart R, van Klaveren RJ, Wang Y, Bogoni L, et al: Performance of computer-aided detection of pulmonary nodules in low-dose CT: comparison with double reading by nodule volume. Eur Radiol 2012; 22: 2076-2084.
62. Godoy MC, Kim TJ, White CS, Bogoni L, de Groot P, Florin C, et al: Benefit of computeraided detection analysis for the detection of subsolid and solid lung nodules on thin-and thick-section CT. AJR Am J Roentgenol 2013; 200: 74-83.
63. Wormanns D, Ludwig K, Beyer F, Heindel W, Diederich S: Detection of pulmonary nodules at multirow-detector CT: effectiveness of double reading to improve sensitivity at standard-dose and low-dose chest CT. Eur Radiol 2005; 15: 14-22. (Pubitemid 40109764)
64. van't Westeinde SC, de Koning HJ, Thunnissen FB, Oudkerk M, Groen HJ, Lammers JW, et al: The role of the (1)(8)f-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trial. J Thorac Oncol 2011; 6: 1704-1712.
65. Veronesi G, Bellomi M, Veronesi U, Paganelli G, Maisonneuve P, Scanagatta P, et al: Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg 2007; 84: 959-965, discussion 965-966.
66. Ashraf H, Dirksen A, Loft A, Bertelsen AK, Bach KS, Hansen H, et al: Combined use of positron emission tomography and volume doubling time in lung cancer screening with lowdose CT scanning. Thorax 2011; 66: 315-319.
67. Silva M, Sverzellati N, Manna C, Negrini G, Marchiano A, Zompatori M, et al: Long-term surveillance of ground-glass nodules: evidence from the MILD trial. J Thorac Oncol 2012; 7: 1541-1546.
68. Matsuguma H, Mori K, Nakahara R, Suzuki H, Kasai T, Kamiyama Y, et al: Characteristics of subsolid pulmonary nodules showing growth during follow-up with CT scanning. Chest 2013; 143: 436-443.
69. Van Schil PE, Asamura H, Rusch VW, Mitsudomi T, Tsuboi M, Brambilla E, et al: Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J 2012; 39: 478-486.
70. Graham G, Blaha MJ, Budoff MJ, Rivera JJ, Agatston A, Raggi P, et al: Impact of coronary artery calcification on all-cause mortality in individuals with and without hypertension. Atherosclerosis 2012; 225: 432-437.
71. van de Wiel JC, Wang Y, Xu DM, van der Zaag-Loonen HJ, van der Jagt EJ, van Klaveren RJ, et al: Neglectable benefit of searching for incidental findings in the Dutch-Belgian lung cancer screening trial ( NELSON) using low-dose multidetector CT. Eur Radiol 2007; 17: 1474-1482. (Pubitemid 46767595)
72. Priola AM, Priola SM, Giaj-Levra M, Basso E, Veltri A, Fava C, et al: Clinical implications and added costs of incidental findings in an early detection study of lung cancer by using low-dose spiral computed tomography. Clin Lung Cancer 2013; 14: 139-148.
73. Kucharczyk MJ, Menezes RJ, McGregor A, Paul NS, Roberts HC: Assessing the impact of incidental findings in a lung cancer screening study by using low-dose computed tomography. Can Assoc Radiol J 2011; 62: 141-145.
74. National Center for Disease Control and Prevention: Smoking and Tobacco Use. 2013. http://www.cdc.gov/tobacco/tobacco-control-programs/(accessed August 8, 2013).
75. McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, et al: Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 2011; 6: 1841-1848.
76. Goulart BH, Bensink ME, Mummy DG, Ramsey SD: Lung cancer screening with lowdose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012;10:267-275.
77. Pyenson BS, Sander MS, Jiang Y, Kahn H, Mulshine JL: An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. Health Aff (Millwood) 2012; 31: 770-779.